Accepted Manuscript

Title: Therapeutic opportunities for targeting cold pain pathways

Author: Kathleen Yin Katharina Zimmermann Irina Vetter Richard J. Lewis

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1   **Graphical**

2   **abstract**

3

1

Therapeutic opportunities for targeting cold pain pathways

3

4 Kathleen Yin[1,2], Katharina Zimmermann[3], Irina Vetter[1,2], Richard J. Lewis[1]

5

6 [1]Institute for Molecular Biosciences, The University of Queensland, St Lucia, Queensland 4072, Australia

7 [2]School of Pharmacy, The University of Queensland, Woolloongabba, Queensland 4102, Australia

8 [3]Department of Physiology and Pathophysiology, Friedrich-Alexander University of Erlangen-Nuremberg,

9 91054 Erlangen, Germany

10

11

12

13 **Abstract:** Cold pain is a frequent symptom in neuropathic pain. Compared to other pain

14 modalities, such as heat pain, the mechanisms behind physiological and pathological cold

15 pain remain elusive. Moreover, it is becoming increasingly evident that cold pain

16 pharmacology differs between various neuropathic pain conditions, making mechanism-

17 directed treatment based on an understanding of the underlying pathophysiological

18 mechanisms imperative to achieving clinical success. Here we review the processes of

19 physiological and abnormal cold sensing, the pharmacology of cold nociception, cold

20 hyperalgesia and cold allodynia, and provide an overview of cold pain syndromes and their

21 current and potential treatments.

22

25

26 The authors declare no conflict of interest.

2

1

2

3 **<u>Introduction</u>**

4   The perception of temperature is vital for human survival. As homoeothermic animals,

5 humans rely on temperature regulation mechanisms to maintain a constant body temperature

6 of ~ 37 °C irrespective of activity or the external environment. However, while innocuous hot

7 or cold is considered harmless and often pleasurable, temperature extremes are painful and

8 interpreted as signs of impeding tissue damage. The sensation of pleasant cool is usually

9 elicited at temperatures just below normal skin temperature (32 °C), with temperatures

10 approaching 10–15 °C and below gradually eliciting burning, aching and pricking pain [1-3].

11 Indeed, many of us are familiar with the excruciating pain that follows consumption of cold

12 beverages or food, resulting in a cold-induced headache also known as "brain freeze".

13 Similarly, immersion in ice-cold water is a commonly used nociceptive assessment in sensory

14 testing to quantify an individual's pain threshold [4]. In this review, we describe the different

15 cold pain pathways, ion channels involved in cold pain signalling, their involvement in

16 pathological cold pain, and discuss mechanisms of current and potential new treatments for

17 cold pain that might alleviate chronic cold pain sensitisation.

18

19 **Cold pain pathways**

20   Specific peripheral nerves activated by innocuous cold were discovered almost a century

21 ago, first in the cat [5] and later in primates, where *in vivo* studies in anesthetised animal

22 identified peripheral nerve fibres that discharged action potentials in response to cold

23 stimulation of their receptive fields [6, 7]. Initially, these studies identified afferent fibres that

24 only responded to innocuous temperatures (below 27 °C) and not to heat or mechanical

25 stimuli. The firing frequency of these cold-sensitive neurons, later regarded as 'classic'

3

1   innocuous cold thermosensors, is inversely proportional to temperature, with peak discharge

2   rates occurring on cooling between 30 and 25 °C [7]. Since this early discovery, other cold-

3   sensitive sensory fibre subtypes were characterised in primates and in other species, as shown

4   in **Table 1** [6-13]. Subsets of slow-conducting (typically < 1 m/s) C-fibres are monomodal

5   and sense innocuous and noxious cold or are multimodal mechanothermal nociceptors, with

6   the remaining cold-sensitive neurons classified as fast-conducting (up to 16 m/s) Aδ-fibres [3,

7   13-15]. Given that C-fibres sensitive to noxious cold are mostly polymodal nociceptors that

8   respond to other stimuli, including mechanical stimulation, it appears likely that C-fibres

9   conduct pain signals without discriminating the nature of the stimuli, while Aδ-fibres

10 recognise the discomfort is caused specifically by cold [7, 16]. It is thus very likely that the

11 full sensation of cold pain requires the presence of both C- and Aδ-fibres.

12   In humans, the physiological cold pain threshold is significantly more variable than the

13 heat pain threshold, with temperatures below approximately 15 °C eliciting pain. Broadly, the

14 intensity of cold pain increases rapidly between approximately 20 and 0 °C [1, 2, 17]. In

15 rodents, frank nocifensive behaviour on contact exposure to cold surfaces is usually only

16 elicited at temperatures below 5 °C [18, 19], which may reflect the relative insensitivity of

17 these behavioural assays to detect mild to moderate pain-related behaviours in rodents.

18   Centrally, temperature signals reach the brain via the lateral spinothalamic tract, whereas

19 pain signals are additionally carried via the spinoreticular and spinothalamic tracts, which

20 terminate in the thalamus and the frontal cortices, respectively [20-23]. In healthy humans,

21 stimulation of the forearm skin with innocuous cold leads to activation of the contra- and

22 ipsilateral- posterior insular cortices as the primary somatosensory area [24]. In contrast,

23 noxious cold stimuli activate the contra- and ipsilateral- insular cortices and secondary

24 somatosensory cortices and the cingulate cortex, as revealed by magnetoencephalography

25 [24]. Functional magnetic resonance imaging has been employed to investigate brain areas

4

1   activated during menthol-induced cold allodynia, identifying increased activation within the

2   ipsilateral dorsolateral prefrontal cortices and the brainstem (ipsilateral parabrachial nucleus)

3   [25]. These observations illustrate some of the differences between the brain regions

4   responsible for innocuous cold, cold pain, and pathological cold pain. In contrast, the

5   molecular mechanisms underlying central cold pain processing are less clear. Studies to date

6   have revealed that the beneficial effects of spinal cord stimulation were abolished by

7   serotonin receptor antagonists in a murine spinal nerve ligation model [26], and that ablating

8   neuropeptide Y receptors in the superficial spinal dorsal horn reduced cold allodynia in CFA-

9   induced inflammation in rats [27]. Interestingly, μ-opioid receptor binding potential in the

10   striatum predicted cold pressor test threshold in humans, but not cold tolerance, possibly

11   correlating peripheral cold pain threshold with central opioid-dependent inhibition [28].

12

13   **Pathological Cold Pain Conditions**

14   Pathological cold pain is a frequent symptom in a range of neuropathic pain syndromes,

15   including those of peripheral and central origin, and usually presents as cold allodynia or

16   hyperalgesia [29]. While many conditions, including diabetic neuropathy, peripheral nerve

17   injury, chemotherapy-induced neuropathy, post-stroke central pain and ciguatera (see **Table

18   2**) can present with the symptom of pathological cold pain, the mechanisms by which cold

19   pain arise are still poorly understood and can vary significantly between diseases [30-35].

20   A condition that is defined by cold allodynia is ciguatera, a form of marine food poisoning

21   arising from the consumption of tropical and subtropical fish contaminated with ciguatoxins.

22   Ciguatoxins originate from dinoflagellates of the *Gambierdiscus* family and accumulate in

23   reef fish through the marine food chain [36]. Symptoms of ciguatera include dysaesthesias,

24   headache, dental pain, and myalgia, with cold allodynia occurring in almost all ciguatera

25   patients (for review see [36]). Experiments with human volunteers showed that intracutaneous

5

1   injection of ciguatoxin induced local cold allodynia which faded after a few hours, suggesting

2   ciguatoxin acts acutely and peripherally to cause cold pain [37]. Similarly, mice of the

3   C57BL/6 strain develop cold, but not mechanical or heat allodynia, within one hour after

4   intraplantar ciguatoxin injection, an effect that is mediated predominantly through peripheral

5   sensory neurons expressing the transient receptor potential (TRP) cold sensor TRPA1 [38].

6   In contrast, cold allodynia elicited after intraplantar injection of the chemotherapeutic

7   agent oxaliplatin involved sensory neurons expressing voltage-gated sodium channel (Na_v)

8   subtype 1.6 and voltage-gated potassium channel (K_v) channels, and developed independent

9   of cold-sensitive TRP channels [39]. While oxaliplatin is administered intravenously in

10   humans, intraplantar injection of oxaliplatin in mice recapitulated the immediate-onset cold-

11   induced dysaesthesias that often occur in humans undergoing therapy with the platinum-

12   derived anti-tumour agent. The immediate occurrence of painful symptoms after

13   subcutaneous oxaliplatin exposure in mice implies that primary sensory effects are sufficient

14   to elicit cold allodynia. However, the long-lasting progression of the disease in humans after

15   intravenous infusion does not exclude an altered expression of cold-sensing TRP channels

16   contributing or aggravating the disease at a later stage, as found for TRPA1 or TRPM8 in

17   mouse models of chronic oxaliplatin-induced neuropathy [40-43].

18   Treatment with paclitaxel, a chemotherapy agent used in the management of solid tumours

19   such as breast cancer, is also associated with a high incidence of cold allodynia. Paclitaxel-

20   induced cold allodynia commences in the hands and feet and gradually progresses centrally.

21   Cold allodynia appears to parallel the development of paclitaxel-induced neuropathy with

22   signs such as demyelination, accumulation of abnormal mitochondria in sensory nerves, and

23   fibre loss in severe cases [44, 45]. Subcutaneous injection of tetrodotoxin (TTX) reduced

24   paclitaxel-induced mechanical, heat and cold allodynia [46], suggesting the involvement of

25   TTX-sensitive Na_v isoforms as observed for oxaliplatin-induced cold allodynia.

6

1   Interestingly, diabetic animals with pre-existing peripheral neuropathy are more susceptible

2   to develop cold allodynia when treated with paclitaxel [45]. This is perhaps not surprising as

3   diabetic neuropathy, a late symptom of chronic diabetes, is in itself a complex neuropathic

4   pain syndrome associated with cold allodynia and increased TRPA1 gene expression. More

5   than 50% of patients diagnosed with diabetes will eventually develop diabetic neuropathy,

6   which is characterised by distal paraesthesias and dysaesthesias, including cold-induced

7   allodynia and hyperalgesia [47, 48]. The causes of diabetic neuropathy are multifactorial,

8   revolving around the cellular results of chronic hyperglycaemia which in turn cause oxidative

9   stress and cellular damage [49]. While the precise pathophysiological mechanisms leading to

10   cold pain in diabetic neuropathy remain to be elucidated, abnormal peripheral sensory nerve

11   function, including functional changes of the molecular players implicated in cold sensing, are

12   likely to be involved. For example, methylglyoxal, an endogenous reactive metabolite,

13   contributes to gain-of-function dysregulation of peripheral sensory neurons by increasing

14   signalling through voltage-gated sodium channels and the cold-sensitive receptor TRPA1 [50,

15   51].

16   Cold intolerance also occurs in over 40% of patients with upper-extremity nerve trauma or

17   hand/finger amputation and in generalised pain states such as complex regional pain

18   syndrome, and may involve both peripheral sensory neuron abnormalities as well as altered

19   central processing [52-55]. In addition to dysfunction of peripheral nerves, changes in central

20   signalling can also lead to cold allodynia. For example, central post-stroke pain (CPSP) is a

21   chronic pain condition [56, 57] that features painful symptoms in the body parts related to the

22   brain territory affected by the cerebrovascular lesion. Estimations about cold pain prevalence

23   are difficult because pre-existing chronic pain disorders are frequent [56]. Nevertheless,

24   thermal allodynia is a frequent sensory symptom of CPSP and the allodynia presumably arises

25   when CNS structures that form parts of somatosensory pathways, such as the medulla,

7

1   thalamus, and cortex, are among damaged areas [56]. Interestingly, brain lesions alone are

2   insufficient to cause cold allodynia, suggesting additional secondary pathophysiological

3   changes contribute to the development of cold allodynia following a stroke [56].

4

5   **Ion Channels Involved in Cold Pain**

6   Cold temperature detection involves the process of sensory transduction in the cutaneous

7   primary sensory nerve terminals, which converts a thermal stimulus into depolarisation of the

8   membrane. This transformation into an electrical signal is followed by the subsequent

9   propagation of the action potentials in the cold-sensitive afferent nerves. A large array of ion

10 channels, including TRPs and sodium and potassium channels, shape this process as outlined

11 below **(Fig. 1).**

12

13 **TRP Channels**

14 **Cold-sensitive TRPM8:** The discovery of the transient receptor potential melastatin 8

15 channel (TRPM8) [58, 59] has significantly advanced our understanding of the processes

16 underlying transduction and transformation of external cold into electrical signals. The

17 channel is essential for the detection of environmental cold, and a series of potassium channels

18 contribute to threshold adjustment and amplification of TRPM8-dependent cold transduction

19 [60-62]. TRPM8$^{-/-}$ mice show drastically reduced responses to innocuous cold [63-65].

20 Cultured trigeminal ganglia from TRPM8$^{-/-}$ mice are also insensitive to menthol or innocuous

21 cold (22 °C), while the number of cold-responsive cutaneous myelinated and unmyelinated

22 nerve endings is decreased significantly [63]. However, the extent to which TRPM8 is

23 essential for pathological forms of cold pain is controversial, and conflicting evidence exists,

24 as outlined in **Table 3**.

8

1   TRPM8[-/-] mice, mice treated with intrathecal TRPM8 antisense oligonucleotide, and mice

2   with diphtheria toxin-mediated ablation of TRPM8-positive neurons all had reduced

3   physiological cold sensitivity, but also reduced cold hypersensitivity following Complete

4   Freund's Adjuvant (CFA)-induced inflammation and chronic constriction injury (CCI), as

5   examined by the acetone test [64, 66, 67]. At the same time, TRPM8[-/-] mice retain noxious

6   cold sensitivity and exhibit similar nocifensive behaviours to control mice at temperatures

7   below 10 °C [63, 65]. A further confounding factor in studies assessing the contribution of

8   TRPM8 to cold sensing and cold pain is the specificity and selectivity of pharmacological

9   "tool" compounds such as menthol. Many studies equate menthol-induced responses or effects

10 with selective TRPM8 activation. However, the prototypical TRPM8 agonist menthol, as

11 discussed below, is a promiscuous compound and elicits responses in TRPM8-negative

12 sensory neurons. Menthol inhibits nicotinic acetylcholine receptors [68], inactivates voltage-

13 gated calcium currents [69], inhibits $K_v7.2/7.3$ channels [60], and activates and/or desensitises

14 the cold-sensitive TRPA1 channel [70].

15

16 **Cold-sensitive TRPA1:** TRPA1 is considered a noxious cold and irritant sensor. The

17 channel mediates, among others, the reaction to the pungent components of mustard,

18 horseradish, and wasabi. TRPA1 is also activated by formaldehyde, bacterial endotoxins and

19 pro-inflammatory mediators such as bradykinin, methylglyoxal, and prostaglandin E2 [50, 71-

20 79]. TRPA1 expression in sensory neuronal populations overlaps little with TRPM8

21 expression, suggesting distinct physiological functions for the two channels. Moreover,

22 TRPA1 is not only highly co-expressed with the noxious heat sensor TRPV1, but can also

23 form functional heteromultimers [80], which adds to the functional complexity of this channel.

24 Activation of TRPA1 by cold in cellular models varies between species [81] and has been

25 investigated extensively, as summarised in **Table 4**. The overwhelming majority of studies

9

1 assessed TRPA1 activation by cold using cultured rodent dorsal root ganglion (DRG) neurons,

2 or rodent TRPA1 overexpressed in mammalian HEK293 cells, CHO cells, or *Xenopus*

3 oocytes. Many such studies demonstrated increased intracellular Ca^{2+} or TRPA1-mediated

4 inward current upon exposure to cool temperatures (5-18 °C ; see **Table 4**) [59, 77, 81-86].

5 However, while questions about the cold-sensitivity of TRPA1 have been raised [61, 74, 81,

6 87, 88], species- and tissue-specific differences in the cold sensitivity of TRPA1 are becoming

7 apparent. A number of studies also based their conclusions regarding the cold sensitivity of

8 TRP channels on the perhaps erroneous assumption of the pharmacological specificity of

9 isothioscyanates, icilin and menthol [59, 70, 74, 89-92]. In fact, while rodent TRPA1 is cold-

10 sensitive, snake and drosophila TRPA1 are heat-sensitive [87, 93, 94]. In TRPA1-deficient

11 mice, altered nocifensive behaviour in various noxious cold tests has been described and is

12 summarised in **Table 5**. In addition, a recent functional MRI study unveiled altered central

13 processing of cold stimuli at temperatures above the noxious cold range (15 °C) where no

14 measurable aversive behaviour is observed, suggesting that standard cold pain tests in mice

15 are less sensitive than commonly believed [38]. In contrast to mice TRPA1, primate TRPA1

16 does not respond to cooling in *in vitro* systems [81]. Nevertheless, a distinct role for TRPA1 in

17 cold sensing and cold pain in humans cannot be denied, as a monogenic TRPA1 gain-of-

18 function mutation is linked to a hereditary disease of episodic debilitating pain, which is

19 triggered by cold [95]. Turning to ciguatoxin as a model of cold allodynia, *de novo* TRPA1-

20 mediated cold responses in previously cold-insensitive mouse DRG neurons emerged after

21 treatment with ciguatoxin and correlate well with a key contribution of TRPA1 to ciguatoxin-

22 induced cold allodynia in mice [38]. Comparable mechanisms of TRPA1 sensitisation to cold

23 may apply for cold hypersensitivity in inflammatory conditions and diabetic neuropathy [50,

24 71, 83, 96]. In addition, evidence for TRPA1 contribution to neuropathic cold allodynia of

25 various origins is brought together in **Table 5**.

10

1   Insight into the biophysical mechanisms underlying temperature-sensitivity of TRP

2   channels comes from a range of elegant studies assessing gating behavior of TRP channel

3   chimeras and orthologs. Although temperature can have a profound effect on general

4   phospholipid phase transitions, conformational changes, and protein denaturation, the

5   remarkable effect of temperature on thermo-TRP function likely arises from direct effects on

6   structural components which alter channel open probability [97]. In the case of TRPA1,

7   residues contributing to thermal sensitivity appear to be located in the region of the N-terminal

8   ankyrin domains which converted the cold-sensitive mouse TRPA1 into a heat-gated channel

9   akin to the rattlesnake TRPA1 ortholog [87, 98], while point mutations within the S5 and S6

10   transmembrane domain rendered rodent and drosophila TRPA1, respectively, temperature-

11   insensitive [81, 99]. Similarly, replacement of the TRPM8 C-terminus with the corresponding

12   TRPV1 sequence reversed the temperature-dependence of the channel [100]. In addition,

13   temperature and voltage exert synergistic, or allosteric, effects on channel gating, with cooling

14   shifting the voltage-dependence of TRPM8 activation closer to physiological membrane

15   potential [101].

16

17   **Cold-sensitive TRPC5**: The recent discovery of the involvement of the TRPC5 channel in

18   peripheral cold sensation has recently expanded the list of cold-sensitive channels [102] and

19   may provide an explanation for the TRPM8- and TRPA1-independent cold sensitivity

20   observed in peripheral sensory neurons [90]. TRPC5 homomers, but not TRPC5-TRPC1

21   heteromultimers, are most active between 37 and 25 °C [102]. In mice and humans, TRPC5 is

22   expressed at all levels of the nociceptive system, including sensory nerve endings, axons,

23   DRG neurons and the superficial nociceptive laminae in the spinal cord [102]. TRPC5$^{-/-}$ mice,

24   based on the 129S1/SvImJ strain, had fewer TRPM8-expressing DRG neurons but

25   significantly higher numbers of cutaneous CMC-fibres with increased sensitivity to cold and

11

1 menthol. However, at the behavioural level, no differences appeared in the cold plate and the

2 two-plate temperature preference assays. Rather than being a noxious cold sensor, TRPC5

3 probably mediates changes in detection and regional adaption to cold. Cold-induced gating of

4 TRPC5 is potentiated by activation of Gq-coupled receptors, which modulates cold sensing by

5 TRPC5 [102]. Neither oxaliplatin nor ciguatoxin-activated models of cold allodynia involve

6 TRPC5 [38, 39] .

7

8 **Voltage-gated sodium channels**

9    $Na_v1.1$, $Na_v1.2$, $Na_v1.6$, $Na_v1.7$, $Na_v1.8$ and $Na_v1.9$ are the Na_v isoforms expressed in adult

10 DRG neurons and co-localise to a variable degree with peripherin, a marker of non-myelinated

11 C-fibre neurons and with neurofilament, which stains medium and large diameter neurons

12 associated with A-fibres. While $Na_v1.6$ localises to all sizes of neurons, $Na_v1.7$, $Na_v1.8$ and

13 $Na_v1.9$ predominate the small neurons. In contrast, $Na_v1.1$ is exclusively confined to large

14 neurons [103]. $Na_v1.3$ is the major Na_v subtype in embryonic neurons and is present in

15 sympathetic neurons [104], but undetectable in adult DRGs, where it re-emerges after injuries

16 such as axotomy [105]. Given their diverse roles in cold pain pathways, it is likely that these

17 subtypes contribute to modality- and pathway-specific pain, including nociceptive cold pain,

18 cold allodynia and cold hyperalgesia as discussed below.

19

20 **$Na_v1.7$:** $Na_v1.7$ has gained prominence as a putative pain target, with rare genetic mutations

21 rendering $Na_v1.7$ non-functional in humans causing cases of congenital insensitivity to pain

22 (CIP), without affecting the ability to discriminate hot from cold [106-109]. Its contribution to

23 physiological and pathological cold pain was assessed using three different $Na_v1.7$ knockout

24 mouse strains (see **Table 6**): $Na_v1.7^{Nav1.8}$, with $Na_v1.7$ deleted from $Na_v1.8$-expressing

25 neurons; $Na_v1.7^{Advill}$, with $Na_v1.7$ deleted from all sensory neurons; and $Na_v1.7^{Wnt1}$, with

12

1    $Na_v1.7$ deleted from sensory and sympathetic neurons [110]. Deletion of $Na_v1.7$ from $Na_v1.8$-

2   expressing nociceptors reduced but did not abolish withdrawal responses to an acetone drop

3   applied to the hind paw, while cold nociception was virtually abolished in $Na_v1.7^{Advill}$ and

4    $Na_v1.7^{Wnt1}$ animals [110]. Although this suggests a crucial role for $Na_v1.7$ in $Na_v1.8$-negative

5   neurons during cold nociception, all three $Na_v1.7$ knockout mouse lines displayed normal

6   temperature preference behaviour between 30 °C and 5 °C [110]. Additionally, $Na_v1.7$ in

7   DRG neurons is essential for cold allodynia in the CCI-model of neuropathic pain, but not in

8   the sympathetically mediated spinal nerve transection (SNT) model of neuropathic pain,

9   which only requires $Na_v1.7$ in sympathetic neurons. Consistent with these roles, $Na_v1.7$ does

10   not contribute to oxaliplatin-induced cold allodynia [39, 111].

11

12   **$Na_v1.8$:** Low-threshold TTX-sensitive ion channels such as $Na_v1.7$ enter a state of slow

13   inactivation upon cooling at temperatures lower than 26 °C [112]. In contrast, the high-

14   threshold, slow TTX-resistant $Na_v1.8$ is resistant to cold-induced slow inactivation and

15   remains available to generate action potentials at noxious cold temperatures. Consequentially,

16   $Na_v1.8$ expressing C-fibres predominate our perceptions in cold temperatures, while Aβ-fibre

17   mediated mechanosensitivity and manual dexterity is lost [112]. Thus, $Na_v1.8$ is not only

18   responsible for pain caused by noxious cold, but also for any other pain modality at low

19   temperatures. Accordingly, cold pain thresholds are significantly increased in $Na_v1.8$ global

20   knockout animals and after diphtheria toxin-mediated ablation of $Na_v1.8$-expressing DRG

21   neurons [110, 112, 113] (see **Table 7)**. Similar to $Na_v1.7$, the contribution of $Na_v1.8$ to

22   pathological cold pain appears to be modality- and disease-specific. In the post-CCI cold

23   allodynia model, $Na_v1.8$ knock-out mice showed attenuated flinching responses to acetone,

24   while in the post-SNT cold allodynia model the withdrawal responses of $Na_v1.8$ knock-out

25   animals were similar to wild-type litter mates [111].

13

1    $Na_v1.8$ appears less important in conditions where cold allodynia occurs at more moderate

2   temperatures, potentially because TTX-sensitive Na_v isoforms remain functional. This is likely

3   the case for ciguatoxin-induced cold allodynia, where $Na_v1.8$-expressing C-fibre nociceptive

4   pathways contribute partially to cold pain behaviour in concert with TTX-sensitive ion

5   channels on A-fibre pathways [38]. In contrast to ciguatoxin, cold allodynia elicited by

6   intraplantar injection of the chemotherapeutic agent oxaliplatin is mediated entirely by TTX-

7   sensitive Na_v isoforms, and cold pain behaviour at 10 °C was not affected in $Na_v1.8$ knockout

8   animals, or after treatment with the $Na_v1.8$ inhibitor A803467 [39]. These findings were also

9   confirmed in a more conventional model where cold allodynia develops slowly after repeated

10   intravenous administration of oxaliplatin [111] and which was independent of $Na_v1.7$, $Na_v1.8$,

11   and TRP channels.

12

13   **$Na_v1.6$ and $Na_v1.3$:** Involvement of $Na_v1.3$ in pain behaviour seems minor, despite being

14   upregulated in various inflammatory and neuropathic pain conditions [114-116]. Some

15   contribution of $Na_v1.3$ was shown in CCI, but not in the sciatic nerve ligation (SNL) or

16   oxaliplatin-induced models of cold allodynia [39, 111]. Indeed, oxaliplatin-induced cold

17   allodynia was completely abolished by TTX and the $Na_v1.6$ inhibitor GIIIA, while inhibition

18   by subtype-selective modulators or genetic deletion of other Na_v isoforms, including $Na_v1.7$

19   and $Na_v1.3$, had no effect [39]. Although activation of $Na_v1.6$ by the scorpion toxin Cn2 was

20   not sufficient to cause cold allodynia, it amplified cold pain caused by potassium channel

21   inhibition [39]. Indeed, oxaliplatin is likely to elicit direct effects on $Na_v1.6$-expressing

22   sensory neurons independent of changes in neuronal viability or frank neuronal toxicity. When

23   exposed to oxaliplatin, compound after-potentials were triggered in A-fibres from human

24   nerve fascicles upon cooling, but not in C-fibres [117]. This effect was abolished in sural

25   nerve fascicles from SCN8A$^{med/med}$ mice that lack functional $Na_v1.6$ [117]. Oxaliplatin also

14

1   induced $Na_v1.6$-mediated resurgent and persistent currents in large (but not small) diameter

2   DRG neurons in response to cooling, and significantly slowed inactivation of heterologously

3   expressed $Na_v1.6$ [117]. These effects corroborate a crucial role for $Na_v1.6$ in cold pain

4   pathways. Indeed, the contribution of $Na_v1.6$ to cold pain may extend to other conditions, as

5   ciguatoxin-induced cold allodynia was also partially inhibited by the $Na_v1.6$ inhibitor GIIIA

6   [37].

7

8   **Potassium channels**

9   A range of potassium channels, including the two-pore domain (2PK) background channels

10   TRAAK, TASK-3, TREK-1, TRESK [118, 119] as well as voltage-gated potassium channels

11   K_v1 and $K_v7.2/7.3$, have been implicated in the physiology of cold sensing and the

12   pathophysiology of cold pain. Closure of background 2PK channels underpins cooling-

13   induced increase in excitability of cultured DRG neurons, leading to membrane depolarisation

14   and increased firing [120, 121].

15   TREK-1 and TRAAK are temperature- and mechano-sensitive background potassium

16   channels of the 2PK family [122, 123] that stabilise the resting membrane potential at normal

17   skin and body temperature. Their closure with cooling and heating facilitates temperature

18   transduction-induced membrane depolarisation in C-fibres [120, 121, 123, 124]. However,

19   while C-fibres from TREK-1 knock-out mice exhibit a reduced heat threshold, these mice did

20   not display any difference in cold sensitivity compared to control during the acetone test and

21   cold water tail immersion [124]. A more detailed analysis using temperature-controlled cold

22   plates revealed that TREK-1 knock-out mice had reduced cold avoidance at 18°C but not at

23   other temperatures [62], although cold allodynia (as evidenced by decreased paw withdrawal

24   responses in the acetone test) was decreased in TREK-1$^{-/-}$ mice after SNL [124].

15

1   TRAAK knockout mice, like TREK-1 knockouts, had normal cold-sensitive C-fibres and

2   no cold sensing deficits in the cold plate assay, the temperature-preference assay from 27 °C

3   to 12 °C, or in cold allodynia following CCI [62]. A cold sensing phenotype became apparent

4   only when both TREK1 and TRAAK were removed. The double knockout mice showed cold

5   hypersensitivity in the 30°C thermal preference test, increased cold avoidance in the cold plate

6   test, and increased cold allodynia post-CCI [62]. Thu,s during cold allodynia, where normally

7   silent sensory neurons increasingly respond to mild cooling, reduced background potassium

8   conductance may contribute to altered thermal thresholds and heightened cold sensitivity.

9   The presence of 4-aminopyridine-sensitive K_v channels appears to define cold-insensitive

10   neurons [61, 121]. Activity of these channels prevents firing of cold-insensitive neurons

11   during cooling by acting as excitability brakes. In addition, the setting of the temperature

12   threshold in cultured trigeminal neurons is conferred by equilibrium between TRPM8 and K_v1

13   channels. Indeed, the temperature threshold of trigeminal neurons is defined by balanced

14   expression of the cold-sensitive thermosensor TRPM8 and K_v1 channels, with cold-sensitive

15   neurons defined by large TRPM8-mediated responses and low K_v1 current density, while the

16   inverse relationship is true for cold-insensitive neurons [61].

17   Investigating ion channel constellations in low- and high-threshold cold-sensitive DRG

18   neurons revealed that $K_v1.1$ and $K_v1.2$ selective blockers increased baseline calcium levels of

19   high-threshold cold sensors but not low-threshold sensors, confirming differential expression

20   of K_v1 channels in cold-sensitive neurons responsive to different temperature ranges [85].

21   Selective $K_v1.2$ block converted high-threshold cold sensors into low-threshold cold sensors

22   that respond to minor fluctuations in temperature (± 1 °C) [85]. This effect translates to

23   increased nocifensive behaviour of mice on a 0 °C cold plate and increased flinching in the

24   acetone test after intraplantar injection of a K_v1 channel blocker [61]. These results support a

25   pivotal role of K_v1 channels in setting the temperature threshold of cultured DRGs with high,

16

1   but not low threshold, cold-sensitivity. Whether K_v1 channels also contribute to the setting of

2   the temperature thresholds, and thereby shape the broad dynamic range of monomodal cold-

3   sensitive fibres in the murine skin, has not been investigated so far.

4   A similar inverse relationship exists for K_v7 availability and temperature threshold of

5   activation in cutaneous cold nociceptive nerve fibre terminals [60]. While K_v7 expression

6   levels or current density cannot be determined in terminal nerve endings, the cold sensitising

7   effect of the K_v7 inhibitors XE991 and camphor were directly correlated to the fibre's

8   temperature threshold, with low threshold cold-sensitive fibres showing little cold sensitisation

9   in response to K_v7 inhibition [60]. Instead, relatively cold-insensitive fibres with high

10 temperature thresholds showed pronounced cold sensitisation in response to both camphor and

11 XE991 [60]. However, treatment with the K_v7 specific inhibitor XE991 or camphor, an M-

12 channel inhibitor and weak TRPM8 agonist, were unable to trigger a cold response in the

13 absence of TRPM8, suggesting that K_v7 channels act as suprathreshold amplifiers of the cold-

14 activated generator potential provided by TRPM8 [60]. In addition, menthol appears to be an

15 M-channel   inhibitor   and   thus   combines   dual   cold-activating   and   cold-sensitising

16 pharmacology in one molecule [60].

17

18 **Animal Models of Cold Pain**

19   Rodent models are widely used to assess the contribution of various ion channels to cold

20 sensing and nociception as well as cooling-induced allodynia and hyperalgesia, largely due to

21 the accessibility of rodents in a laboratory setting and the ease of genetic manipulation in mice

22 in particular. However, results from rodent studies, especially mice, are limited by difficulties

23 relating to behavioural responses to pain sensation in animals, with poor distinction often

24 made between innocuous cool, cold and noxious cold. Overt aversive behaviours upon

25 exposure to temperature-controlled surfaces such as paw lifting, licking, flinching, shaking or

17

1   jumping occur at temperatures below 5 °C, suggesting this should be considered the threshold

2   for noxious cold in rodents [19]. Moreover, large variation in response latency occurs in the

3   traditional measure of hind paw withdrawal upon contact with a 0 °C cold plate, which can

4   range from 5-200 seconds in several independent reports [63-65, 78]. Attempts to correlate

5   more subtle changes in exploratory behaviour, such as walking backwards, to cold-induced

6   pain responses have been reported [125]. Nevertheless, the validity and reproducibility of such

7   approaches are unclear. An alternative approach to quantification of cold-induced pain

8   behaviour is to assess latency to forepaw rather than hind paw withdrawal or shaking, an

9   approach used successfully to assess the contribution of TRPM8 to noxious cold sensing at 0

10   °C [66, 82].

11   Another measure of cold avoidance is the temperature preference assay. The two-plate

12   temperature preference assay allows animals to choose between two adjacent surfaces

13   maintained at different temperatures, while the temperature gradient assay determines a

14   preference temperature directly by using a continuous gradient. In these assays, choosing the

15   appropriate temperature range is crucial as differences in phenotype or behaviour can only be

16   detected if the thermal environment lies in the appropriate range of being mildly aversive

17   without being overtly noxious. However, although clear differences in time spent at cool

18   temperatures are apparent in models such as TRPM8$^{-/-}$ animals, it is not entirely clear to what

19   degree these assays reflect physiological warmth preference rather than a sensation of pain, or

20   aversion to cool.

21   The acetone test consists of applying a drop or a small spray of acetone to one hind paw,

22   which then leads to evaporation-induced cooling and aversive behaviour. Application of

23   acetone to the hind paw is often considered an innocuous cold stimulus as a decrease of

24   approximately ~8-12 °C in skin temperature can be achieved with this technique [64, 126]. An

25   additional advantage of the acetone test is the ability to stimulate unilateral aversive

18

1 behaviour, which may be easier to quantify. However, application of acetone to the hind paw

2 of mice, and to a lesser degree of rats, elicits withdrawal responses in some naïve animals

3 [64], suggesting the use of the acetone evaporation test is not suitable for quantification of

4 cold allodynia and may more accurately represent general noxious withdrawal responses.

5 Acetone-evoked withdrawal responses may also incorporate elements of mechanical

6 stimulation or aversive responses to the odour of acetone, and control over the rate and degree

7 of cooling is not possible. In addition, acetone has high vapour pressure and a small surface

8 tension, and forming a uniform "drop" on a syringe that can be applied to the animal's hind

9 paw can rarely be achieved.

10 An additional factor to be considered in observer-based behavioural studies is the need for

11 appropriate blinding and randomisation to eliminate conscious, as well as unconscious, bias.

12 This is illustrated by our observation that cold allodynia was erroneously observed when a

13 blinded observer quantified paw withdrawal responses to the application of acetone between

14 two distinct groups of mice while knowing one group was an experimental cohort and the

15 other a control cohort. This effect completely disappeared when individual mice from the two

16 cohorts were observed at random (unpublished observation).

17 Despite the wide availability of animal models of cold allodynia, it is difficult to evaluate

18 how well the pathophysiological mechanisms of animal models translate to human conditions.

19 This difficulty arises in part from differences in the time course of disease and methods used

20 to induce and measure pain behaviour. Currently, animal models are considered adequate as

21 long as the animals exhibit similar neuropathic pain symptoms to human patients after

22 exposure to the same chemicals or injuries. The extent to which such animal models are based

23 on similar disease mechanism as their human equivalents is not always clear and needs to be

24 assessed using well-designed clinical studies.

25

19

1 **Treatment of Pathological Cold Pain**

2 Despite our growing understanding of the pathophysiology of cold pain, treatment of

3 neuropathic cold pain remains largely symptomatic, with standard analgesics and adjuvants

4 used in the majority of conditions associated with cold allodynia or hyperalgesia.

5 Neuropathic pain patients often present with a multitude of sensory abnormalities that are

6 based on diverse pathophysiological mechanisms. Most clinical trials assessing analgesic

7 efficacy for specific diseases rely on visual analogue scales or equivalent self-reporting of pain

8 intensity rather than quantitative sensory testing. In addition, co-morbidities are common in

9 diseases that present with cold allodynia, adding to heterogeneity in the clinical presentation.

10 Accordingly, delineating clinical efficacy for treatment of cold pain specifically is often

11 difficult, although inclusion of quantitative sensory profiling in clinical trials is likely to

12 improve our success in mechanism-based treatment approaches [127].

13 As outlined in the preceding sections, it is becoming increasingly clear that cold pain and

14 cold sensing are complex phenomena involving diverse modality- and disease-specific

15 mechanisms. This complexity is illustrated by the diverse molecular mechanisms underlying

16 cold pain induced by intraplantar injection of ciguatoxin and oxaliplatin. While ciguatoxin-

17 induced cold allodynia requires TRPA1 and is decreased significantly without functional

18 $Na_v1.8$, acute oxaliplatin-induced cold allodynia develops in sensory neurons expressing TTX-

19 sensitive $Na_v1.6$ independent of thermosensitive TRP channels. It is thus likely there will be

20 no single molecular target or drug that can treat the wide pathophysiological spectrum of cold

21 allodynia and hyperalgesia. Nonetheless, mechanism-directed drug therapy for neuropathic

22 pain is on the rise, with drugs targeting TRPA1 and TRPM8 as well as $Na_v1.8$ and $Na_v1.7$

23 considered particularly attractive for treatment of cold pain, albeit the responding patient

24 populations will need to be chosen carefully based on the underlying pathophysiological

25 mechanisms. Based on the role of K^+ channels in setting the temperature threshold in cold-

20

1 sensitive peripheral sensory neurons, K^+ channel agonists may also prove useful in the clinical

2 management of neuropathic cold pain. Indeed, the K^+ channel agonists flupirtine and

3 retigabine were effective at decreasing neuronal excitability in an *in vitro* model of

4 oxaliplatin-induced cold hypersensitivity and also decreased oxaliplatin-induced cold

5 allodynia *in vivo*, as did analgesics with mixed activity at Na_v and K_v channels such as

6 lamotrigine and phenytoin (See **Table 12**) [128, 129].

7 Although selective channel modulators may be a feasible strategy for reducing cold

8 allodynia due to the defined role of many channels such as TTX-sensitive Na_v isoforms,

9 $Na_v1.8$, TRPM8 and TRPA1, limited research on the clinical applications of these findings is

10 available and accurate analgesic efficacy prediction based on cell or rodent models may be

11 difficult. For example, while amitriptyline reduced ciguatoxin-induced calcium influx in *in*

12 *vitro* models, it was not effective at treating ciguatoxin-induced cold allodynia in a rodent

13 model [37]. In the absence of systematic clinical trials in human ciguatera sufferers, this result

14 is consistent with an anecdotal report of lack of efficacy of amitriptyline for treatment of cold

15 hypersensitivity, although the tricyclic antidepressant may be efficacious at treating other

16 symptoms associated with ciguatera [130]. Conversely, the antiepileptic lamotrigine and the

17 analgesic flupirtine were analgesic *in vivo* but had little effect on ciguatoxin-induced Ca^{2+}

18 responses *in vitro*, being 100- and 10-times less potent than amitriptyline, respectively [37].

19 A similar analgesic efficacy profile was observed for oxaliplatin-induced cold allodynia,

20 with lamotrigine, retigabine, and phenytoin being most effective while amitriptyline was not

21 analgesic [128, 131]. Gabapentin as well as Ca^{2+}/Mg^{2+} also partially reduced oxaliplatin-

22 induced cold allodynia [131]. However, while efficacy of Ca^{2+}/Mg^{2+} is in accordance with

23 several clinical studies [132-134], gabapentin was not effective in a randomised controlled

24 trial on oxaliplatin-induced neuropathic pain [135]. In fact, more patients in the gabapentin

25 treatment group developed neuropathy than those in the control group [135]. This apparent

21

1   discrepancy highlights the difficulty in translating findings from cellular models to murine

2   models and human disease. Similarly, venlafaxine displayed effective analgesia in a murine

3   model of oxaliplatin-induced cold allodynia [136], yet did not significantly improve cold

4   allodynia in human patients despite efficacy towards other symptoms of oxaliplatin-induced

5   neuropathy [137]. Curiously, morphine treatment displayed significant benefit in murine

6   models of acute and chronic oxaliplatin-induced cold allodynia [136, 138], while the opioid

7   receptor agonist fentanyl was ineffective at reversing cold allodynia induced by intraplantar

8   injection of oxaliplatin [128].

9   Few human studies have specifically examined analgesic efficacy in paclitaxel-induced

10   cold allodynia. Randomised controlled trials assessing the effect of gabapentin, lamotrigine

11   and glutathione found a lack of efficacy in chemotherapy-induced peripheral neuropathy

12   (CIPN) [139-141]. However, these studies did not specifically investigate cooling-related

13   symptoms. Currently, the most promising treatment targeting paclitaxel-induced cold

14   allodynia that has undergone human trials appears to be duloxetine. In one case study, a

15   patient complaining of persistent and uncontrolled paclitaxel-induced neuropathy was treated

16   unsuccessfully with pregabalin and trazodone. The addition of duloxetine reversed the

17   symptoms and the patient experienced almost no pain two and half months later [142]. While

18   this case study did not specify what type of allodynia the patient suffered from, evidence from

19   a murine model supported the lack of efficacy of pregabalin in cold allodynia after paclitaxel

20   administration [143], while a clinical trial showed duloxetine to be efficacious in CIPN [144].

21   This suggests that duloxetine, but not pregabalin, may be a potential treatment for paclitaxel-

22   induced cold allodynia, although further studies are warranted.

23   In comparison to studies on CIPN, a much larger body of literature is devoted to the current

24   and prospective treatments for diabetic neuropathy. A vast array of drugs, ranging from tight

25   control of blood glucose levels to topical capsaicin applications, are used clinically to treat

22

1 pain and allodynia associated with diabetic neuropathy. Cold allodynia, however, does not

2 present in every case of diabetic neuropathy. Moreover, human clinical trials on diabetic

3 neuropathy frequently use pain scores and visual analogue scales as measurements of

4 analgesia and do not necessarily assess the extent of stimulus-evoked pain or cold allodynia.

5 Trials that include cold pain patients also often do not report separate analysis of modality-

6 specific pain [145, 146]. Therefore, it is often difficult to gauge the specific impact of

7 treatments on cold pain. Notably, clinical studies on lamotrigine, gabapentin, and amitriptyline

8 specified the inclusion of cold pain patients, and the overall results were positive [147, 148]. A

9 rat study also verified that amitriptyline is effective in diabetic animals with associated cold

10 allodynia [149]. However, while venlafaxine and pregabalin were effective for the treatment

11 of diabetic neuropathy, it is unclear if these human trials included patients with cold pain [146,

12 150].

13 Unlike the peripheral neuropathies that are associated with cold pain, central post-stroke

14 pain (CPSP) triggers cold pain through damage to central pain tracts. Its treatment broadly

15 follows that of other neuropathies, with drugs such as pregabalin and amitriptyline effectively

16 alleviating neuropathic pain [151, 152]. While systematic clinical trials assessing analgesic

17 efficacy in CPSP-associated cold pain are largely lacking, treatment with duloxetine for eight

18 weeks significantly decreased cold allodynia evoked by the acetone test in humans [153].

19 Therefore, while CPSP in general can be effectively treated by a variety of drugs commonly

20 used in neuropathic pain, duloxetine appears as a promising new treatment of cold allodynia

21 associated with central nerve injury.

22 With increasing understanding of the pathophysiological mechanisms underlying cold pain,

23 new mechanism-based treatments are being developed. Extensive drug discovery efforts

24 directed at thermosensitive ion channels, most notably TRPA1 and TRPM8, have led to the

25 discovery of a number of molecules with putative analgesic efficacy in cold allodynia. HC-

23

1   030031, a purine acetamide and selective TRPA1 antagonist, has been used extensively in a

2   range of models associated with cold pain (see **Table 5**), with variable effects. Notably, HC-

3   030031 was effective in rodent models of nerve injury and inflammation [83, 154], as was

4   another small molecule TRPA1 inhibitor, A-967079 [155].

5   Presently, a TRPA1 selective antagonists (GRC 17536) is being evaluated in human studies

6   for the treatment of diabetic neuropathy and reached Phase II trials

7   (http://clinicaltrials.gov/ct2/show/NCT01726413), and further Phase I clinical trials have been

8   initiated to assess safety and efficacy of the TRPA1 antagonist CB-625 [156]. In addition, a

9   range of TRPM8 antagonists are being developed currently, including compounds that

10   showed efficacy in rodent models of chronic constriction injury- and oxaliplatin-induced cold

11   allodynia [157]. Other selective TRP as well as Na^+ or K^+ channel modulators remain in the

12   pre-clinical development stage where their efficacy, selectivity, and dose *in vitro* and *in vivo*

13   remain a topic of investigation. Thus, promising new approaches to the treatment of cold pain

14   are on the horizon.

15

16   **Conclusion**

17   This review has highlighted that cold pain and cold sensing are complex phenomena, with

18   clear differences in molecular pathophysiology between conditions associated with cold pain.

19   Peripheral sensory neuron ion channels, such as voltage-gated sodium channels, potassium

20   channels, and TRP channels, are involved to varying degrees in cold nociception,

21   hyperalgesia and allodynia and may be suitable targets for improved treatment of these pain

22   modalities. Notably, in addition to $Na_v1.7$, $Na_v1.8$, TRPA1, TRPM8, K_v1, TRESK, and

23   TRAAK, more recently $K_v7.2/7.3$, TRPC5, and $Na_v1.6$ have also been implicated in cold

24   sensing and pain. In light of the diverse molecular players and mechanisms involved in

25   pathological cold pain, it is not surprising that there is currently no universally effective

24

1 treatment. In addition, the cold pain symptoms present in each neuropathic syndrome are

2 likely to result from specific sets of interactions between peripheral fibres, ion channels, and

3 central modulation. Given this complexity, extensive research is required to unravel the

4 processes underlying neuropathic cold pain and to allow the rational development of new

5 drugs that improve the clinical management of this often-neglected syndrome.

6

11

25

1   **References**

2   [1] Morin C, Bushnell MC. Temporal and qualitative properties of cold pain and heat pain: a
3   psychophysical study. Pain. 1998;74(1):67-73.
4   [2] Hagander LG, Midani HA, Kuskowski MA, Parry GJ. Quantitative sensory testing: effect
5   of site and skin temperature on thermal thresholds. Clin Neurophysiol. 2000;111(1):17-22.
6   [3] Campero M, Serra J, Bostock H, Ochoa JL. Slowly conducting afferents activated by
7   innocuous low temperature in human skin. J Physiol. 2001;535(3):855-65.
8   [4] Mitchell LA, MacDonald RA, Brodie EE. Temperature and the cold pressor test. J Pain.
9   2004;5(4):233-7.
10   [5] Zotterman Y. Specific action potentials in the lingual nerve of cat. Skandinavisches
11   Archiv Für Physiologie. 1936;75(3):105-19.
12   [6] Dubner R, R. Sumino, Wood WI. A Peripheral "Cold" Fiber Population Responsive to
13   Innocuous and Noxious Thermal Stimuli Applied to Monkey's Face. J Physiol.
14   1975;38:1373-89.
15   [7] LaMotte RH, Thalhammer JG. Response Properties of High-Threshold Cutaneous Cold
16   Receptors in the Primate. Brain Res. 1982;244(279-287).
17   [8] Darian-Smith I, Johnson KO, Dykes R. "Cold" fiber population innervating palmar and
18   digital skin of the monkey: responses to cooling pulses. J Neurophysiol. 1973;36(2):325-46.
19   [9] Dykes RW. Coding of steady and transient temperatures by cutaneous "cold" fibers
20   serving the hand of monkeys. Brain Res. 1975;98(3):485-500.
21   [10] Kenshalo DR, Duclaux R. Response characteristics of cutaneous cold receptors in the
22   monkey. J Neurophysiol. 1977;40(2):319-32.
23   [11] Georgopoulos AP. Functional properties of primary afferent units probably related to
24   pain mechanisms in primate glabrous skin. J Neurophysiol. 1976;39(1):71-83.
25   [12] Simone DA, Kajander KC. Responses of cutaneous A-fiber nociceptors to noxious cold.
26   J Neurophysiol. 1997;77(4):2049-60.
27   [13] Simone DA, Kajander KC. Excitation of rat cutaneous nociceptors by noxious cold.
28   Neurosci Lett. 1996;213:53-6.
29   [14] Dubin AE, Patapoutian A. Nociceptors: The sensors of the pain pathway. J Clin Investig.
30   2010;120(11):3760-72.
31   [15] Zimmermann K, Hein A, Hager U, Kaczmarek JS, Turnquist BP, Clapham DE, et al.
32   Phenotyping sensory nerve endings in vitro in the mouse. Nat Protoc. 2009;4(2):174-96.
33   [16] Yarnitsky D, Ochoa JL. Release of cold-induced burning pain by block of cold-specific
34   afferent input. Brain. 1990;113:893-902.
35   [17] Wahren LK, Torebjork E, Jorum E. Central suppression of cold-induced C fibre pain by
36   rnyelinated fibre input. Pain. 1989;38:313-9.
37   [18] Jasmin L, Kohan L, Franssen M, Janni G, Goff JR. The cold plate as a test of nociceptive
38   behaviors: description and application to the study of chronic neuropathic and inflammatory
39   pain models. Pain. 1998;75(2-3):367-82.
40   [19] Allchorne AJ, Broom DC, Woolf CJ. Detection of cold pain, cold allodynia and cold
41   hyperalgesia in freely behaving rats. Mol Pain. 2005;1(36).
42   [20] Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review.
43   Brain Res. 2004;1000(1-2):40-56.
44   [21] Giordano J. The neurobiology of nociceptive and anti-nociceptive systems. Pain
45   Physician. 2005;8(3):277-90.
46   [22] Bester H, Chapman V, Besson JM, Bernard JF. Physiological properties of the lamina I
47   spinoparabrachial neurons in the rat. J Neurophysiol. 2000;83(4):2239-59.
48   [23] Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that
49   modulate pain. J Clin Neurophysiol. 1997;14(1):2-31.

26

[24] Maihöfner C, Kaltenhauser M, Neundorfer B, Lang E. Temporo-spatial analysis of cortical activation by phasic innocuous and noxious cold stimuli – a magnetoencephalographic study. Pain. 2002;100:281-90.

[25] Seifert F, Maihöfner C. Representation of cold allodynia in the human brain—A functional MRI study. Neuroimage. 2007;35:1168-80.

[26] Song Z, Meyerson BA, Linderoth B. Spinal 5-HT receptors that contribute to the pain-relieving effects of spinal cord stimulation in a rat model of neuropathy. Pain. 2011;152:1666–73.

[27] Lemons LL, Wiley RG. Neuropeptide Y receptor-expressing dorsal horn neurons: roles in nocifensive reflex and operant responses to aversive cold after CFA inflammation. Neuroscience. 2012;216:158-66.

[28] Hagelberg N, Aalto S, Tuominen L, Pesonen U, Någren K, Hietala J, et al. Striatal mu-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects. Neurosci Lett. 2012;521:11-4.

[29] Bowsher D, Haggett C. Paradoxical burning sensation produced by cold stimulation in patients with neuropathic pain. Pain. 2005;117(1-2):230.

[30] Rosen L, Eltvik L, Arvesen A, Stranden E. Local cold injuries sustained during military service in the Norwegian Army. Arctic Med Res. 1991;50(4):159-65.

[31] Lindblom U, Verrillo RT. Sensory functions in chronic neuralgia. J Neurol Neurosurg Psychiatry. 1979;42(5):422-35.

[32] Ochoa JL, Yarnitsky D. The triple cold syndrome. Cold hyperalgesia, cold hypoaesthesia and cold skin in peripheral nerve disease. Brain. 1994;117 (Pt 1):185-97.

[33] Beise RD, Carstens E, Kohlloffel LU. Psychophysical study of stinging pain evoked by brief freezing of superficial skin and ensuing short-lasting changes in sensations of cool and cold pain. Pain. 1998;74(2-3):275-86.

[34] Khasabov SG, Cain DM, Thong D, Mantyh PW, Simone DA. Enhanced responses of spinal dorsal horn neurons to heat and cold stimuli following mild freeze injury to the skin. J Neurophysiol. 2001;86(2):986-96.

[35] Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959-64.

[36] Vetter I, Zimmermann K, Lewis RJ. Ciguatera toxins: pharmacology, toxicology and detection. . Seafood and Freshwater Toxins: Pharmacology, Physiology, and Detection. 3rd ed. Boca Raton, FL, USA: Taylor & Francis; 2014.

[37] Zimmermann K, Deuis JR, Inserra MC, Collins LS, Namer B, Cabot PJ, et al. Analgesic treatment of ciguatoxin-induced cold allodynia. Pain. 2013;154(10):1999-2006.

[38] Vetter I, Touska F, Hess A, Hinsbey R, Sattler S, Lampert A, et al. Ciguatoxins activate specific cold pain pathways to elicit burning pain from cooling. EMBO J. 2012;31:3795-808.

[39] Deuis JR, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154:1749-57.

[40] Nassini R, Gees M, Harrison S, Siena GD, Materazzi S, Moretto N, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain. 2011;152:1621-31.

[41] Kono T, Satomi M, Suno M, Kimura N, Yamazaki H, Furukawa H, et al. Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain Behav. 2012;2(1):68-73.

[42] Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3:266-78.

27

[43] Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett. 2009;458:93-5.

[44] Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014;76:175-83.

[45] Barrière DA, Rieusset J, Chanteranne D, Busserolles J, Chauvin M-A, Chapuis L, et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species roduction and TRPA1 sensitization. Pain. 2012;153:553-61.

[46] Nieto FR, Entrena JM, Cendan CM, Pozo ED, Vela JM, Baeyens JM. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain. 2008;137:520-31.

[47] Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-34.

[48] Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006;2(5):269-81.

[49] Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: Current perspective and future directions. Pharmacol Res. 2014;80:21-35.

[50] Eberhardt MJ, Filipovic MR, Leffler A, de la Roche J, Kistner K, Fischer MJ, et al. Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. J Biol Chem. 2012;287(34):28291-306.

[51] Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med. 2012;18(6):926-33.

[52] Smits ES, Selles RW, Huygen FJP, Duraku LS, Hovius SER, Walbeehm ET. Disordered conditioned pain modulation system in patients with posttraumatic cold intolerance. J Plast Reconstr Aesthet Surg. 2013:1-6.

[53] Davis KD, Pope GE. Noxious cold evokes multiple sensations with distinct time courses. Pain. 2002;98:179-85.

[54] Lithell M, Backman C, Nystrom A. Cold intolerance is not more common or disabling after digital replantation than after other treatment of compound digital injuries. Ann Plast Surg. 1998;40:256-9.

[55] Nijhuis THJ, Smits ES, Jaquet JB, Van Oosterom FJT, Selles RW, Hovius SER. Prevalence and severity of cold intolerance in patients after hand fracture. J Hand Surg Eur Vol. 2010;35E(4):306-11.

[56] Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol. 2009;8:857-68.

[57] Flaster M, Meresh E, Biller J. Central Poststroke Pain: Current Diagnosis and Treatment. Topics in Stroke Rehabilitation. 2013;20(2):116-23.

[58] McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 2002;416(6876):52-8.

[59] Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, et al. ANKTM1, a TRP-like Channel Expressed in Nociceptive Neurons, Is Activated by Cold Temperatures. Cell. 2003;112:819-29.

[60] Vetter I, Hein A, Sattler S, Hessler S, Touska F, Bressan E, et al. Amplified Cold Transduction in Native Nociceptors by M-Channel Inhibition. J Neurosci. 2013;33(42):16627-41.

[61] Madrid R, Pena Edl, Donovan-Rodriguez T, Belmonte C, Viana F. Variable Threshold of Trigeminal Cold-Thermosensitive Neurons Is Determined by a Balance between TRPM8 and Kv1 Potassium Channels. J Neurosci. 2009;29(10):3120-31.

[62] Noel J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S, et al. The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J. 2009;28(1308-1318).

[63] Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature. 2007;448:204-9.

[64] Colburn RW, Lubin ML, Stone Jr DJ, Wang Y, Lawrence D, D'Andrea MR, et al. Attenuated Cold Sensitivity in TRPM8 Null Mice. Neuron. 2007;54:379-86.

[65] Dhaka A, Murray AN, Mathur J, Earley TJ, Petrus MJ, Patapoutian A. TRPM8 Is Required for Cold Sensation in Mice. Neuron. 2007;54:371-8.

[66] Knowlton WM, Palkar R, Lippoldt EK, McCoy DD, Baluch F, Chen J, et al. A Sensory-Labeled Line for Cold: TRPM8-Expressing Sensory Neurons Define the Cellular Basis for Cold, Cold Pain, and Cooling-Mediated Analgesia. J Neurosci. 2013;33(7):2837-48.

[67] Su L, Wang C, Yu Y-H, Ren Y-Y, Xie K-L, Wang G-L. Role of TRPM8 in dorsal root ganglion in nerve injury-induced chronic pain. BMC Neurosci. 2011;12(120).

[68] Hans M, Wilhelm M, Swandulla D. Menthol Suppresses Nicotinic Acetylcholine Receptor Functioning in Sensory Neurons via Allosteric Modulation. Chem Senses. 2012;37:463-9.

[69] Swandulla D, Carbone E, Schafer K, Lux HD. Effect of menthol on two types of Ca currents in cultured sensory neurons of vertebrates. Pflueg Arch Eur J Physiol. 1987;409:52-9.

[70] Karashima Y, Damann N, Prenen J, Talavera K, Segal A, Voets T, et al. Bimodal Action of Menthol on the Transient Receptor Potential Channel TRPA1. J Neurosci. 2007;27(37):9874–84.

[71] Andersson DA, Gentry C, Light E, Vastani N, Vallortigara J, Bierhaus A, et al. Methylglyoxal evokes pain by stimulating TRPA1. PLoS ONE. 2013;8(10):e77986.

[72] Ohkawara S, Tanaka-Kagawa T, Furukawa Y, Jinno H. Methylglyoxal activates the human transient receptor potential ankyrin 1 channel. J Toxicol Sci. 2012;37(4):831-5.

[73] Meseguer V, Alpizar YA, Luis E, Tajada S, Denlinger B, Fajardo O, et al. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. Nat Commun. 2014;5:3125.

[74] Jordt S-E, Bautista DM, Chuang H-h, McKemy DD, Zygmunt PM, Hogestatt ED, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature. 2004;427:260-5.

[75] Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, et al. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007;445(7127):541-5.

[76] McKemy DD. How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain. 2005;1(16).

[77] Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, et al. Noxious Cold Ion Channel TRPA1 Is Activated by Pungent Compounds and Bradykinin. Neuron. 2004;41:849-57.

[78] Bautista DM, Jordt S-E, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269-82.

[79] McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al. TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci U S A. 2007;104(33):13525-30.

1 [80] Fischer MJ, Balasuriya D, Jeggle P, Goetze TA, McNaughton PA, Reeh PW, et al. Direct
2 evidence for functional TRPV1/TRPA1 heteromers. Pflueg Arch Eur J Physiol. 2014.
3 [81] Chen J, Kang D, Xu J, Lake M, Hogan JO, Sun C, et al. Species differences and
4 molecular determinant of TRPA1 cold sensitivity. Nat Commun. 2013;4(2501).
5 [82] Karashima Y, Talavera K, Everaerts W, Janssens A, Kwan KY, Vennekens R, et al.
6 TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci U S A.
7 2008;106(4):1273–8.
8 [83] del Camino D, Murphy S, Heiry M, Barrett LB, Earley TJ, Cook CA, et al. TRPA1
9 Contributes to Cold Hypersensitivity. J Neurosci. 2010;30(45):15165–74.
10 [84] Sawada Y, Hosokawa H, Hori A, Matsumura K, Kobayashi S. Cold sensitivity of
11 recombinant TRPA1 channels. Brain Res. 2007;1160:39-46.
12 [85] Teichert RW, Memon T, Aman JW, Olivera BM. Using constellation pharmacology to
13 define comprehensively a somatosensory neuronal subclass. Proc Natl Acad Sci U S A. 2013.
14 [86] Fajardo O, Meseguer V, Belmonte C, Viana F. TRPA1 Channels Mediate Cold
15 Temperature Sensing in Mammalian Vagal Sensory Neurons: Pharmacological and Genetic
16 Evidence. J Neurosci. 2008;28(31):7863–75.
17 [87] Cordero-Morales JF, Gracheva EO, Julius D. Cytoplasmic ankyrin repeats of transient
18 receptor potential A1 (TRPA1) dictate sensitivity to thermal and chemical stimuli. Proc Natl
19 Acad Sci U S A. 2011;108(46):E1184–E91.
20 [88] Zurborg S, Yurgionas B, Jira JA, Caspani O, Heppenstall PA. Direct activation of the ion
21 channel TRPA1 by Ca2+. Nat Neurosci. 2007;10(3):277-9.
22 [89] Reid G. ThermoTRP channels and cold sensing: what are they really up to? Pflueg Arch
23 Eur J Physiol. 2005;451:250-63.
24 [90] Munns C, Al Qatari M, Koltzenburg M. Many cold sensitive peripheral neurons of the
25 mouse do not express TRPM8 or TRPA1. Cell Calcium. 2007;41(4):331-42.
26 [91] Alpizar YA, Boonen B, Gees M, Sanchez A, Nilius B, Voets T, et al. Allyl
27 isothiocyanate sensitizes TRPV1 to heat stimulation. Pflueg Arch Eur J Physiol.
28 2014;466(3):507-15.
29 [92] Gees M, Alpizar YA, Boonen B, Sanchez A, Everaerts W, Segal A, et al. Mechanisms of
30 transient receptor potential vanilloid 1 activation and sensitization by allyl isothiocyanate.
31 Mol Pharmacol. 2013;84(3):325-34.
32 [93] Gracheva EO, Ingolia NT, Kelly YM, Cordero-Morales JF, Hollopeter G, Chesler AT, et
33 al. Molecular basis of infrared detection by snakes. Nature. 2010;464(7291):1006-11.
34 [94] Viswanath V, Story GM, Peier AM, Petrus MJ, Lee VM, Hwang SW, et al. Opposite
35 thermosensor in fruitfly and mouse. Nature. 2003;423(6942):822-3.
36 [95] Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, et al. A Gain-of-Function
37 Mutation in TRPA1 Causes Familial Episodic Pain Syndrome. Neuron. 2010;66:671-80.
38 [96] Koivisto A, Chapman H, Jalava N, Korjamo T, Saarnilehto M, Lindstedt K, et al.
39 TRPA1: a transducer and amplifier of pain and inflammation. Basic Clin Pharm Toxicol.
40 2014;114(1):50-5.
41 [97] Clapham DE, Miller C. A thermodynamic framework for understanding temperature
42 sensing by transient receptor potential (TRP) channels. Proc Natl Acad Sci U S A.
43 2011;108(49):19492–7.
44 [98] Jabba S, Goyal R, Sosa-Pagan JO, Moldenhauer H, Wu J, Kalmet B, et al. Directionality
45 of Temperature Activation in Mouse TRPA1 Ion Channel Can Be Inverted by Single-Point
46 Mutations in Ankyrin Repeat Six. Neuron. 2014;82(5):1017-31.
47 [99] Wang H, Schupp M, Zurborg S, Heppenstall PA. Residues in the pore region of
48 Drosophila transient receptor potential A1 dictate sensitivity to thermal stimuli. J Physiol.
49 2013;591:185-201.

30

[100] Brauchi S, Orta G, Salazar M, Rosenmann E, Latorre R. A Hot-Sensing Cold Receptor: C-Terminal Domain Determines Thermosensation in Transient Receptor Potential Channels. J Neurosci. 2006;26(18):4835-40.

[101] Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B. The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature (Lond). 2004;430(7001):748-54.

[102] Zimmermann K, Lennerz JK, Hein A, Link AS, Kaczmarek JS, Delling M, et al. Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. Proc Natl Acad Sci U S A. 2011;108(44):18114-9.

[103] Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci. 2010;33:325-47.

[104] Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A. 2006;103(21):8245-50.

[105] Black JA, Cummins TR, Plumpton C, Chen YH, Hormuzdiar W, Clare JJ, et al. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J Neurophysiol (Bethesda). 1999;82:2776-85.

[106] Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894-8.

[107] Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 2007;71(4):311-9.

[108] Staud R, Price DD, Janicke D, Andrade E, Hadjipanayis AG, Eaton WT, et al. Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain. Eur J Pain. 2011;15(3):223-30.

[109] Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchennykh M, Aasly J. Two novel SCN9A mutations causing insensitivity to pain. Pain. 2009;143(1-2):155-8.

[110] Minett MS, Nassar MA, Clark AK, Passmore G, Dickenson AH, Wang F, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3(791).

[111] Minett MS, Falk S, Santana-Varela S, Bogdanov YD, Nassar MA, Heegaard A-M, et al. Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms. Cell Reports. 2014;6:301-12.

[112] Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW, Kobayashi J-i, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007;447:855-8.

[113] Abrahamsen B, Zhao J, Asante CO, Cendan CM, Marsh S, Martinez-Barbera JP, et al. The Cell and Molecular Basis of Mechanical, Cold, and Inflammatory Pain. Science. 2008;321:702-5.

[114] Hains BC, Klein JP, Saab CY, Craner MJ, Black JA, Waxman SG. Upregulation of Sodium Channel Nav1.3 and Functional Involvement in Neuronal Hyperexcitability Associated with Central Neuropathic Pain after Spinal Cord Injury. J Neurosci. 2003;23(26):8881-92.

[115] Iwahashi Y, Furuyama T, Inagaki S, Morita Y, Takagi H. Distinct regulation of sodium channel types I, II and III following nerve transection. Mol Brain Res. 1994;22:341-5.

[116] Nassar MA, Baker MD, Levato A, Ingram R, Mallucci G, McMahon SB, et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain. 2006;2:33.

31

1 [117] Sittl R, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, et al. Anticancer drug
2 oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-
3 resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109(17):6704-9.
4 [118] Kang D, Kim D. TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background K+
5 channels in dorsal root ganglion neurons. Am J Physiol Cell Physiol. 2006;291:C138-C46.
6 [119] Morenilla-Palao C, Luis E, Fernandez-Pena C, Quintero E, Weaver JL, Bayliss DA, et
7 al. Ion Channel Profile of TRPM8 Cold Receptors Reveals a Role of TASK-3 Potassium
8 Channels in Thermosensation. Cell Reports. 2014;8:1-12.
9 [120] Reid G, Flonta M-L. Cold transduction by inhibition of a background potassium
10 conductance in rat primary sensory neurones. Neurosci Lett. 2001;297:171-4.
11 [121] Viana F, Peña Edl, Belmonte C. Specificity of cold thermotransduction is determined
12 by differential ionic channel expression. Nat Neurosci. 2002;5(3):254-60.
13 [122] Patel AJ, Honore E, Maingret F, Lesage F, Fink M, Duprat F, et al. A mammalian two
14 pore domain mechano-gated S-like K+ channel. EMBO J. 1998;17(15):4283-90.
15 [123] Maingret F, Lauritzen I, Patel AJ, Heurteaux C, Reyes R, Lesage F, et al. TREK-1 is a
16 heat-activated background K+ channel. EMBO J. 2000;19(11):2483-91.
17 [124] Alloui A, Zimmermann K, Mamet J, Duprat F, Noel J, Chemin J, et al. TREK-1, a K+
18 channel involved in polymodal pain perception. EMBO J. 2006;25:2368-76.
19 [125] Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S. Acute Cold
20 Hypersensitivity Characteristically Induced by Oxaliplatin is caused by the enhanced
21 responsiveness of TRPA1 in mice. Mol Pain. 2012;8:55.
22 [126] Leith JL, Koutsikou S, Lumb BM, Apps R. Spinal processing of noxious and innocuous
23 cold information: differential modulation by the periaqueductal gray. J Neurosci.
24 2010;30(14):4933-42.
25 [127] Baron R, Dickenson AH. Neuropathic pain: Precise sensory profiling improves
26 treatment and calls for back-translation. Pain. 2014.
27 [128] Deuis JR, Lim YL, Sousa SRd, Lewis RJ, Alewood PF, Cabot PJ, et al. Analgesic
28 effects of clinically used compounds in novel mouse models of polyneuropathy induced by
29 oxaliplatin and cisplatin. Neuro-oncol. 2014;0:1-9.
30 [129] Sittl R, Carr RW, Fleckenstein J, Grafe P. Enhancement of axonal potassium
31 conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute
32 neuropathy. Neurotoxicology. 2010;31:694-700.
33 [130] Calvert GM, Hryhorczuk DO, Leikin JB. Treatment of ciguatera fish poisoning with
34 amitriptyline and nifedipine. J Toxicol Clin Toxicol. 1987;25(5):423-8.
35 [131] Zhao M, Nakamura S, Miyake T, So K, Shirakawa H, Tokuyama S, et al.
36 Pharmacological characterization of standard analgesics on oxaliplatin-induced acute cold
37 hypersensitivity in mice. J Pharm Sci. 2014;124(4):514-7.
38 [132] Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al.
39 Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in
40 Adjuvant Colon Cancer: NCCTG N04C7. J Clin Oncol. 2011;29(4):421-7.
41 [133] Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, et al.
42 Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions: A
43 Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and
44 Leucovorin for Advanced Colorectal Cancer. Clin Cancer Res. 2004;10:4055-61.
45 [134] Knijn N, Tol J, Koopman M, Werter MJBP, Imholz ALT, Valster FAA, et al. The effect
46 of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and
47 clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer
48 patients. Eur J Cancer. 2011;47:369 –74.

32

[135] Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, et al. Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity. Clin Colorectal Cancer. 2006;6(2):146-51.

[136] Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225-34.

[137] Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23:200-5.

[138] Ling B, Coudore F, Decalonne L, Eschalier A, Authier N. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology. 2008;55:724-8.

[139] Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Daniel A. Nikcevich M, et al. Efficacy of Gabapentin in the Management of Chemotherapy-induced Peripheral Neuropathy: A Phase 3 Randomized, Double-Blind, Placebo-controlled, Crossover Trial (N00C3). Cancer. 2007;110:2110-8.

[140] Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, et al. Efficacy of Lamotrigine in the Management of Chemotherapy-induced Peripheral Neuropathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Trial, N01C3. Cancer. 2008;112:2802-8.

[141] Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North Central Cancer Treatment Group/Alliance Trial N08CA - The Use of Glutathione for Prevention of Paclitaxel/Carboplatin-Induced Peripheral Neuropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Cancer. 2014.

[142] Takenaka M, Iida H, Matsumoto S, Yamaguchi S, Yoshimura N, Miyamoto M. Successful Treatment by Adding Duloxetine to Pregabalin for Peripheral Neuropathy Induced by Paclitaxel. American Journal of Hospice and Palliative Medicine. 2012;30(7):734-6.

[143] Salat K, Cios A, Wyska E, Sałat R, Mogilski S, Filipek B, et al. Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacol Biochem Behav. 2014;122(173-181).

[144] Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial. JAMA (J Am Med Assoc). 2013;309(13):1359-67.

[145] Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: A randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34:818-22.

[146] Tolle T, Freynhagen R, Versavel M, Trostmann U, Young Jr JP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study. Eur J Pain. 2008;12:203–13.

[147] Eisenberg E, Alon N, Ishay A, Daoud D, Yarnitsky D. Lamotrigine in the treatment of painful diabetic neuropathy. Eur J Neurol. 1998;5:167-73.

[148] Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Gregory A. Sahagian. Randomized Double-blind Study Comparing the Efficacy of Gabapentin With Amitriptyline on Diabetic Peripheral Neuropathy Pain. Arch Intern Med. 1999;159:1931-7.

[149] Kim SO, Kim HJ. Berberine Ameliorates Cold and Mechanical Allodynia in a Rat Model of Diabetic Neuropathy. J Med Food. 2013;16(6):511-7.

33

[150] Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2008;22:241-5.

[151] Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27-36.

[152] Vranken JH, Dijkgraaf MGW, Kruis MR, Van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150-7.

[153] Vranken JH, Hollmann MW, Van der Vegt MH, Kruis MR, Heesen M, Vos K, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. Pain. 2011;152:267-73.

[154] Eid SR, Crown ED, Moore EL, Liang HA, Choong K-C, Dima S, et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain. 2008;4(48).

[155] Chen J, Joshi SK, DiDomenico S, Perner RJ, Mikusa JP, Gauvin DM, et al. Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain. 2011;152:1165–72.

[156] Preti D, Szallasi A, Patacchini R. TRP channels as therapeutic targets in airway disorders: a patent review. Expert Opinion on therapeutic patents. 2012;22(6):663-95.

[157] Chaudhari SS, Kadam AB, Khairatkar-Joshi N, Mukhopadhyay I, Karnik PV, Raghuram A, et al. Synthesis and pharmacological evaluation of novel N-aryl-3, 4-dihydro-10H-spiro[chromene-2,40-piperidine]-10-carboxamides as TRPM8 antagonists. Bioorg Med Chem. 2013;21:6542–53.

[158] Lynn B, Carpenter SE. Primary afferent units from the hairy skin of the rat hind limb. Brain Res. 1982;238:29-43.

[159] Hogan D, Baker AL, Morón JA, Carlton SM. Systemic morphine treatment induces changes in firing patterns and responses of nociceptive afferent fibers in mouse glabrous skin. Pain. 2013;154:2297-309.

[160] Treede R-D, Meyer RA, Campbell JN. Myelinated Mechanically Insensitive Afferents From Monkey Hairy Skin: Heat-Response Properties. J Neurophysiol. 1998;80:1082-93.

[161] Bagnis R, Kuberski T, Laugier S. Clinical observations on 3009 cases of ciguatera fish poisoning in the South Pacific. Am J Trop Med Hyg. 1979;28(6):1067-73.

[162] Lawrence DN, Enriquez MB, Lumish RM, Maceo A. Ciguatera fish poisoning in Miami. JAMA (J Am Med Assoc). 1980;244:254-8.

[163] Lange WR, Snyder FR, Fudala PJ. Travel and Ciguatera Fish Poisoning. JAMA Internal Medicine. 1992;152(2049-2053).

[164] Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39(1):128-35.

[165] Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997;35:47-53.

[166] Bowsher D. Allodynia in Relation to Lesion Site in Central Post-Stroke Pain. J Pain. 2005;6(11):736-40.

[167] Kim JS, Choi-Kwon S. Sensory Sequelae of Medullary Infarction: Differences Between Lateral and Medial Medullary Syndrome. Stroke. 1999;30:2697-703.

[168] Vestergaard K, Nielsen J, Andersen G, Ingeman-Nielsen M, Arendt-Nielsen L, Jensen TS. Sensory abnormalities in consecutive, unselected patients with central post-stroke pain. Pain. 1995;61:177-86.

34

[169] Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, et al. Analgesia Mediated by the TRPM8 Cold Receptor in Chronic Neuropathic Pain. Curr Biol. 2006;16:1597-605.

[170] Gentry C, Stoakley N, Andersson DA, Bevan S. The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity. Mol Pain. 2010;6(4).

[171] Obata K, Katsura H, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Investig. 2005;115(9):2393-401.

[172] Katsura H, Obata K, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, et al. Antisense knock down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp Neurol. 2006;200:112-23.

[173] Leo S, D'Hooge R, Meert T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res. 2010;208:149-57.

[174] Lindia JA, Kohler MG, Martin WJ, Abbadie C. Relationship between sodium channel Nav1.3 expression and neuropathic pain behavior in rats. Pain. 2005;117:145-53.

[175] Amaya F, Wong H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, et al. The Voltage-Gated Sodium Channel Nav1.9 Is an Effector of Peripheral Inflammatory Pain Hypersensitivity. The Journal of Neuroscience. 2006;26(50):12852–60.

[176] Beyreuther B, Callizot N, Stöhr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539:64-70.

[177] Brussee V, Guo G, Dong Y, Cheng C, Martinez JA, Smith D, et al. Distal Degenerative Sensory Neuropathy in a Long-Term Type 2 Diabetes Rat Model. Diabetes. 2008;57(6):1664-73.

[178] Ohta A, Kato H, Nakamura Y, Tenjin A, Sakai K, Tukiyama H, et al. Cold-loaded pain sensation test and current perception threshold for evaluating diabetic neuropathy. Diabetology International. 2013;4:34-9.

[179] Hoffman PA, Granade HR, McMillan JP. The mouse ciguatoxin bioassay: a dose-response curve and symptomatology analysis. Toxicon. 1983;21(3):363-9.

[180] Aoki M, Mori A, Nakahara T, Sakamoto K, Ishii K. Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats. Eur J Pharmacol. 2012;696:62-9.

[181] Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepère C, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain. 2009;144:245-52.

[182] Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium Channel Blockade May Contribute to the Analgesic Efficacy of Antidepressants. J Pain. 2007;8(4):315-24.

[183] Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the a2d Subunit of a Calcium Channel. J Biol Chem. 1996;271(10):5768–76.

[184] Grunze H, Von Wegerer J, Greene RW, Walden J. Modulation of Calcium and Potassium Currents by Lamotrigine. Neuropsychobiology. 1998;38:131-8.

35

1   **Table 1.** Peripheral nerve subtypes involved in sensing innocuous and noxious cold

Fibre type	Fibre subtype	Sensitivity	References
C-fibres	CC (C-cold)	Only respond to cold, menthol-sensitive	[3, 6, 15, 102, 158]
	CMHC (C-mechano-heat-cold)	Polymodal nociceptors, respond to noxious mechanical, heat and cold	[14, 60, 159]
	CMC (C-mechano-cold)	Polymodal nociceptors, respond to noxious mechanical and cold	[13, 60, 158, 159]
	High-threshold cold-sensitive fibres	Only respond to noxious cold (< 20 °C)	[7]
Aδ-fibres	Low-threshold cold-sensitive fibres	Respond to innocuous cold	[160]
	AδMHC (Aδ-mechano-heat-cold)	Polymodal nociceptors, respondto noxious mechanical, heat and cold	[13, 159]
	AδMC (Aδ-mechano-cold) fibres	Polymodal nociceptors, respondg to noxious mechanical and cold	[159]
	Mechano-insensitive cold-sensitive fibres	Respond to innocuous or noxious cold	[6, 160]

2

3

1   **Table 2.** Common neuropathic pain conditions exhibiting symptoms of cold allodynia

Conditions associated with Pathological Cold Pain	Cold Pain Prevalence
Ciguatera	71-88% [161-163]
Oxaliplatin-induced neuropathy	81-98% [164]
Paclitaxel-induced neuropathy	84% [165]
Diabetic neuropathy	Uncertain
Central post-stroke pain (CPSP)	17-70% [166-168]
Post-traumatic cold intolerance following upper limb injury	38-82% [52, 54, 55]

2

3

37

1   **Table 3**. TRPM8 in *in vivo* behavioural models of cold pain

2

Model	Pain test	Inhibition	Cold sensitivity	Species	Ref
Nociception					
Paw	Acetone test	KO	Reduced	Mouse	[63]
	Temperature preference test (30 °C vs 25-5 °C)	KO	Reduced	Mouse	
	10 °C, 0 °C, -5 °C and -10 °C cold plates	KO	Reduced	Mouse	
	0 °C cold plate. Temperature preference test (room temperature vs 25/5 °C)	KO	Reduced	Mouse	[64]
	15 – 53.5 °C multi-zone plate	KO	Reduced	Mouse	[65]
	Acetone test	KO	Reduced	Mouse	
	-1°C cold plate	KO	Unchanged	Mouse	
	Icilin (intraperitoneal)	KO	Reduced	Mouse	
	Acetone test	KO	Reduced	Mouse	[66]
	Icilin (intraperitoneal)				
	0 °C cold plate				
	Temperature preference test (5-50 °C)				
	Acetone test	TRPM8-positive DRG neurons ablated by diphtheria toxin		Mouse	
	Icilin (intraperitoneal)				
	0 °C cold plate				
	Temperature preference test (5-50 °C)				
Inflammation					
Complete Freund's Adjuvant injection (CFA)	Acetone test	KO	Reduced	Mouse	[64]
	Acetone test	KO	Reduced	Mouse	[66]
	Acetone test	TRPM8-positive DRG neurons ablated by diphtheria toxin	Reduced	Mouse	
Nerve injury					
CCI	Acetone test	KO	Reduced	Mouse	[64]
	Acetone test	KO	Reduced	Mouse	[66]
	Acetone test	TRPM8-positive DRG neurons ablated by diphtheria toxin	Reduced	Mouse	
	4 °C cold plate	Local KO with oligonucleotides	Reduced	Rat	[67]
	4 °C cold plate	Menthol (intrathecal)	Increased	Rat	
	1-cm-deep 4 °C water on cage floor	Local KO with oligonucleotides	Reduced	Rat	[169]

38

Neuropathies					
Ciguatoxin	15 °C cold plate	KO	Unchanged	Mouse	[38]
	15 °C cold plate	AMTB (intraplantar)	Unchanged	Mouse	
Oxaliplatin	Temperature preference test (25 °C vs 21/23 °C)	KO	Reduced	Mouse	[42]
	10 °C cold plate	KO	Unchanged	Mouse	[39]
	10 °C cold plate	AMTB (intraplantar)	Unchanged	Mouse	
	10 °C cold plate	M8-B (intraplantar)	Unchanged	Mouse	
	Acetone test	Capsazepine (intraperitoneal)	Reduced	Mouse	[43]
	Acetone test	Capsazepine (intraperitoneal)	Unchanged	Mouse	[40]

1

2

39

1   **Table 4**. TRPA1 in *in vitro* models of cold pain

Model	Species	Temp	Respond to cold	Comment	Ref
CHO cells	Mouse	9 °C	Yes	Increased inward current	[77]
	Mouse	10 °C	Yes	Inward current increase	[82]
	Mouse	17 –11 °C	Yes	Calcium influx and inward current increase	[59]
Xenopus oocytes	Human	5 °C	Yes	Increased inward current	[77]
	Mouse	5 °C	Yes	Increased inward current	
	Rattlesnake	15 – 45 °C	No	Rattlesnake, rat snake, *Drosophila* TRPA1 responded to >38°C. Human TRPA1 responded to neither heat or cold	[87]
	Rat snake	15 – 45 °C	No		
	Drosophila	15 – 45 °C	No		
	Human	15 – 45 °C	No		
	Mouse	5 °C	Yes	Inward current increase	[59]
HEK cells	Rat	10 °C	Yes	Increased inward current	[83]
	Rat	24 – 8 °C	Yes	Calcium influx and inward current increased for rat and mouse TRPA1, but not for human or Rhesus monkey TRPA1	[81]
	Mouse	24 – 8 °C	Yes		
	Human	24 – 8 °C	No		
	Rhesus monkey	24 – 8 °C	No		
	Mouse	16 – 5 °C	Yes	Calcium influx and inward current increase	[84]
	Human	10 °C	No	Calcium influx increased for both TRPA1-positive and control cells upon cold stimulation	[88]
	Human	5 °C	No	No calcium influx	[74]
Cultured DRG neurons	Rat	10 °C	Yes	Increased inward current	[83]
	Mouse	16 – 5 °C	Yes	Calcium influx increase	[84]
	Rat	17/5 °C	Yes	Many rat cold-sensitive neurons express TRPA1, very few mouse cold sensors express the channel	[85]
	Mouse	17/5 °C	No		
Cultured trigeminal neurons	Mouse	16 – 8 °C	No	No increase in calcium influx	[61]
	Mouse	25 – 10 °C	Yes	Calcium influx increase	[82]
	Rat	5 °C	No	No cold response in neurons responsive to mustard oil	[74]
Nodose ganglion neurons	Rat	12 °C	Yes	Ca^{2+} responses and currents in vagal neurons	[86]

2

3

1   **Table 5**. TRPA1 in *in vivo* behavioural models of cold pain

Model	Pain test	Inhibition	Cold sensitivity	Species	Ref
Nociception					
Paw	0 °C cold plate	KO	Reduced	Mouse	[83]
	-5 °C cold plate	HC-030031 (intraperitoneal)	Unchanged	Rat	
	0 °C cold plate	KO	Reduced	Mouse	[82]
	10 °C cold plate	KO	Reduced	Mouse	[170]
	Acetone test	KO	Reduced	Mouse	[170]
	5 – 0 °C cold plate	A-967079 (oral)	No effect	Mouse	[155]
Tail	-10 °C tail immersion	KO	Reduced	Mouse	[82]
Inflammation					
CFA	5 °C cold plate	HC-030031 (intraperitoneal)	Reduced	Rat	[83]
	5 °C cold plate. Hind paw immersion in water at 28 °C, 16 °C, and 4 °C	Local KO with oligonucleotides	Reduced	Rat	[171]
Nerve injury					
CCI	Acetone test	A-967079 (oral)	Reduced	Rat	[155]
SNL	10 °C cold plate	HC-030031 (intraperitoneal)	Reduced	Rat	[83]
	5 °C cold plate	Local KO with oligonucleotides	Reduced	Rat	[172]
	5 °C cold plate. Hind paw immersion in water at 28 °C, 16 °C, and 4 °C	Local KO with oligonucleotides	Reduced	Rat	[171]
Neuropathies					
Ciguatoxin	15 °C cold plate	KO	Reduced	Mouse	[38]
Oxaliplatin	10 °C tail immersion	HC-030031 (intragastric)	Reduced	Rat	[40]
	Acetone test	KO	Reduced	Mouse	
	10 °C cold plate	HC-030031 (intraplantar)	Unchanged	Mouse	[39]
	10 °C cold plate	KO	Unchanged	Mouse	
	30–1 °C dynamic cold plate	HC-030031 (intraperitoneal)	Unchanged	Mouse	[42]

2

3

1   **Table 6.** Na$_v$1.7 in *in vivo* behavioural models of cold pain

Model	Pain test	Inhibition	Cold sensitivity	Species	Reference
Nociception					
Paw	Acetone test	Na$_v$1.7^{Advill}	Reduced	Mouse	[110]
	Temperature preference test (30 °C and 5 °C cold plates)	Na$_v$1.7^{Advill}	Unchanged	Mouse	
	Acetone test	Na$_v$1.7$^{Nav1.8}$	Unchanged	Mouse	
	Temperature preference test (30 °C and 5 °C cold plates)	Na$_v$1.7$^{Nav1.8}$	Unchanged	Mouse	
	Acetone test	Na$_v$1.7^{Wnt1}	Reduced	Mouse	
	Temperature preference test (30 °C and 5 °C cold plates)	Na$_v$1.7^{Wnt1}	Unchanged	Mouse	
Nerve injury					
Spare nerve injury (SNI)	Acetone test	Na$_v$1.7^{Advill}	Unchanged	Mouse	[111]
	Acetone test	Na$_v$1.7$^{Nav1.8}$	Unchanged	Mouse	
	Acetone test	Na$_v$1.7^{Wnt1}	Reduced	Mouse	
CCI	Acetone test	Na$_v$1.7^{Advill}	Reduced	Mouse	
	Acetone test	Na$_v$1.7$^{Nav1.8}$	Reduced	Mouse	
	Acetone test	Na$_v$1.7^{Wnt1}	Reduced	Mouse	
Neuropathies					
Ciguatoxin	15 °C cold plate	ProTxII (intraplantar)	Unchanged	Mouse	[37]
Oxaliplatin	Acetone test	Na$_v$1.7^{Wnt1}	Unchanged	Mouse	[111]
	10 °C cold plate	ProTxII (intraplantar)	Unchanged	Mouse	[39]

2

3

1   **Table 7.** Na$_v$1.8 in *in vivo* behavioural models of cold pain

Model	Pain test	Inhibition	Cold sensitivity	Species	Reference
Nociception					
Paw	Temperature preference test (30 °C and 5 °C cold plates)	KO	Reduced	Mouse	[110]
	Acetone test	KO	Unchanged	Mouse	
	0 °C cold plate	KO	Reduced	Mouse	[112]
	0 °C cold plate	Na$_v$1.8-positive DRG neurons ablated by diphtheria toxin	Reduced	Mouse	[113]
Nerve injury					
SNI	Acetone test	KO	Unchanged	Mouse	[111]
	Acetone test	KO	Reduced	Mouse	[173]
CCI	Acetone test	KO	Reduced	Mouse	[111]
	Acetone test	KO	Unchanged	Mouse	[173]
Neuropathies					
Ciguatoxin	15 °C cold plate	A803467 (intraplantar)	Reduced	Mouse	[38]
	15 °C cold plate	Na$_v$1.8-positive DRG neurons ablated by diphtheria toxin	Reduced	Mouse	
	15 °C cold plate	KO	Reduced	Mouse	
Oxaliplatin	15 °C cold plate	A803467 (intraplantar)	Unchanged	Mouse	[37]

2

3

43

1 **Table 8**. Na$_v$1.3 in *in vivo* behavioural models of cold pain

Model	Pain test	Inhibition	Cold sensitivity	Species	Reference
Nerve injury					
SNI	Acetone test	KO	Unchanged	Mouse	[111]
	Acetone test	Intrathecal injection of oligonucleotides	Unchanged	Rat	[174]
CCI	Acetone test	KO	Reduced	Mouse	[111]
Neuropathies					
Ciguatoxin	15 °C cold plate	KO	Unchanged	Mouse	[37]
Oxaliplatin	10 °C cold plate	KO	Unchanged	Mouse	[39]

2

3 **Table 9**. Na$_v$1.6 in *in vivo* behavioural models of cold pain
4

Model	Pain test	Inhibition	Cold sensitivity	Species	Reference
Neuropathies					
Ciguatoxin	15 °C cold plate	GIIIA (intraplantar)	Reduced	Mouse	[37]
Oxaliplatin	10 °C cold plate	GIIIA (intraplantar)	Reduced	Mouse	[39]

5

6 **Table 10**. Na$_v$1.9 in *in vivo* behavioural models of cold pain
7

| Model	Pain test	Inhibition	Cold sensitivity	Species	Reference
Nociception					
Paw	0 °C cold plate	KO	Unchanged	Mouse	[175]
Nerve injury					
SNI	Acetone test	KO	Unchanged	Mouse	[111]
	Acetone test	KO	Reduced	Mouse	[173]
CCI	Acetone test	KO	Reduced	Mouse	[111]
	Acetone test	KO	Reduced	Mouse	[173]
Neuropathies					
Ciguatoxin	15 °C cold plate	KO	Unchanged	Mouse	[38]
Oxaliplatin	10 °C cold plate	KO	Unchanged	Mouse	[39]

8

9

10

44

Table 11: Comparison of animal cold allodynia models with human disease

	Causes of disease	Disease time course	Acute Symptoms	Chronic symptoms
Diabetic neuropathy-induce cold allodynia				
Animal model	Streptozotocin-induced hyperglycaemia	21 days from streptozotocin injection to hyperglycaemia [45, 176]	N/A	Cold allodynia, heat allodynia, heat hyperalgesia, mechanical hyperalgesia [176]
Animal model	Zucker Fatty rats	Hyperglycaemia established from ~8 weeks [177]	N/A	Reduced nerve conduction speed, mechanical allodynia [177]
Human patients	Chronic diabetes mellitus type 1 or 2	A minimum of 6 months to 2 years from diabetes diagnosis to established neuropathy, dependent on hyperglycaemia [147, 150, 178]	N/A	Peripheral pain, tingling, paraesthesia, numbness, reduced vibration perception, nerve conduction abnormalities [147, 178]
Ciguatera				
Animal model	Ciguatoxin (intraplantar)	Immediate [38]	Spontaneous pain, cold allodynia [38]	N/A
Animal model	Ciguatoxin (intraperitoneal)	Immediate [179]	Hypothermia, reduced locomotor activity, hyporeflexia, lachrymation, salivation, diarrhoea	N/A
Human patients	Ingestion of ciguatoxin-contaminated fish	Immediate [161]	Paraesthesia, diarrhoea, abdominal pain, vomiting, headache [161]	Paraesthesia, myalgia, muscle weakness, vertigo, ataxia [161]
Oxaliplatin-induced cold allodynia				
Animal model	Injected oxaliplatin (acute or chronic)	Immediate [39]	Cold allodynia, mechanical allodynia [39, 180]	Mechanical allodynia, cold allodynia [136]
Human patients	Chronic oxaliplatin therapy	Immediately after injection [181] and chronic	Peripheral paraesthesia and cold allodynia [181]	Cold and heat allodynia, impaired vibration detection [181]

45

1 **Table 12.** Common drugs used in the treatment of neuropathic cold allodynia

Drug name	Drug Target	Condition	Effect	Structure	References
Amitriptyline	Serotonin-noradrenaline reuptake inhibitor and Na_v inhibitor [182]	Ciguatera	Uncertain		[37, 163]
		Oxaliplatin-induced	No		[128, 131]
		Diabetic neuropathy	Yes		[148, 149]
Duloxetine	Serotonin-noradrenaline reuptake inhibitor	Paclitaxel-induced	Yes		[142, 144]
		Post-stroke central pain	Yes		[153]
Venlafaxine	Serotonin-noradrenaline reuptake inhibitor	Oxaliplatin-induced	Uncertain		[136, 137]
Pregabalin	Ca_v in the CNS	Oxaliplatin-induced	Uncertain		[138, 143]
		Paclitaxel-induced	No		[142, 143]
Gabapentin	Ca_v inhibitor [183]	Oxaliplatin-induced	Uncertain		[129, 131, 135, 136, 139]
		Diabetic neuropathy	Yes		[148]
Lamotrigine	Na_v, Ca_v inhibitor, K_v activator [184]	Ciguatera	Yes		[37]
		Oxaliplatin-induced	Yes		[128]
		Diabetic neuropathy	Yes		[147]
Phenytoin	Na_v inhibitor	Ciguatera	Yes		[37]
		Oxaliplatin-induced	Yes		[128]
Flupirtine	K_v activator	Ciguatera	Yes		[37]
		Oxaliplatin-induced	Yes		[129]
Retigabine	K_v7 activator	Oxaliplatin-induced	Yes		[128]
Ca^{2+}/Mg^{2+} infusion	Chelation to oxaliplatin metabolite, or Na_v inhibition	Oxaliplatin-induced	Yes		[131-134]

| Morphine | μ-opioid receptor agonist | Oxaliplatin-induced | Yes | | [136, 138] |

1

2

47

1   **Fig. 1. Ion channels involved in cold sensing and cold pain.** A range of neuronal ion

2   channels have been identified that differentially contribute to physiological cold sensing, cold

3   nociception, as well as pathological cold pain states such as cold allodynia and cold

4   hyperalgesia. Transient receptor potential channels TRPA1, TRPM8 and TRPC5 are gated by

5   cold and are involved in transformation of an external thermal stimulus into a neuronal signal.

6   Voltage-gated potassium channels, most notably K_v1 and $K_v7.2/7.3$, act as excitability brakes

7   in cold-insensitive neurons and contribute to setting the temperature threshold. In addition,

8   background potassium channels such as TRAAK and TREK-1, which regulate the resting

9   membrane potential of sensory neurons, are instrumental in reducing neuronal excitability and

10   thus contribute crucially to thermal pain. Voltage-gated sodium channels, including Nav1.7

11   and Nav1.8 are expressed in unmyelinated nociceptive fibres and contribute to neuronal

12   depolarisation and hyper-excitability.

13

14   **Fig. 2. Pharmacology of cold pain pathways.** The molecular mechanisms that integrate to

15   produce cold pain in different disease states are diverse. These include altered signal

16   transduction in myelinated and unmyelinated peripheral sensory nerve endings, altered action

17   potential (AP) propagation, and altered spinal transmission and central processing. Key

18   channels and receptors contributing to physiological and pathological cold pain pathways are

19   illustrated.

48

Figure